SCHEMBL13628154

SCHEMBL13628154

O=C1/C(=N\O)c2ccc(NS(=O)(=O)c3ccc(Cl)cc3)cc2N1Cc1cc(F)cc2c1OCOC2

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 2/20 0.36
CA1 P00915 2/20 0.36
CA2 P00918 2/20 0.36
CA9 Q16790 2/20 0.36
PKM P14618 3/20 0.36
MAPT P10636 4/20 0.36
KDM4E B2RXH2 3/20 0.36
ALDH1A1 P00352 3/20 0.36
HPGD P15428 2/20 0.36
NPSR1 Q6W5P4 2/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
KDR P35968 2/20 0.35
AURKB Q96GD4 2/20 0.35
AURKA O14965 1/20 0.35
ATIC P31939 1/20 0.35
LMNA P02545 2/20 0.34
MAPK1 P28482 1/20 0.34
HTT P42858 1/20 0.34
NPC1 O15118 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13628212 0.90 MAPT (0.40) PKMMAPTKDM4EALDH1A1MEN1
SCHEMBL13628209 0.87 AURKA (0.39) CA12CA1CA2CA9ALDH1A1
SCHEMBL13628210 0.87 AURKA (0.42) CA12CA1CA2CA9MAPT
SCHEMBL13628211 0.85 BRD4 (0.38) CA12CA1CA2CA9ALDH1A1
SCHEMBL13628148 0.85 MAPK8 (0.37) KDM4EALDH1A1NPSR1KDRNPC1
SCHEMBL13628049 0.84 ALDH1A1 (0.40) PKMMAPTALDH1A1MEN1KMT2A
SCHEMBL14269960 0.84 UCHL3 (0.43) CA12CA1CA2CA9MAPT
SCHEMBL13628198 0.82 KMT2A (0.43) MAPTKDM4EALDH1A1HPGDNPSR1
SCHEMBL13628152 0.82 MAPK8 (0.39) KDM4EALDH1A1NPSR1LMNANPC1
SCHEMBL13628199 0.81 MAPT (0.40) MAPTALDH1A1HPGDNPSR1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612065-B2 Inhibitors of c-JUN N-terminal kinases (JNK) VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-11-03 US disclosed
US-7612065-B2 Inhibitors of c-JUN N-terminal kinases (JNK) VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-11-03 US disclosed
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) SALITURO FRANCESCO G 2008-02-07 US disclosed
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) SALITURO FRANCESCO G 2008-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) MAP3K1, JUN, MAP3K7 CA12 4791/4885CA1 3628/4885CA2 3142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.